Literature DB >> 4040927

Characterization of a new model of GM2-gangliosidosis (Sandhoff's disease) in Korat cats.

E A Neuwelt, W G Johnson, N K Blank, M A Pagel, C Maslen-McClure, M J McClure, P M Wu.   

Abstract

We have detected a disorder in Korat cats (initially imported from Thailand) that is analogous to human Sandhoff's disease. Pedigree analysis indicates that this disease in an autosomal recessive disorder in the American Korat. Postmortem studies on one affected cat showed hepatomegaly that was not reported in the only other known feline model of GM2-gangliosidosis type II. Histologic and ultra-structural evaluation revealed typical storage vacuoles. There was a marked deficiency in the activity of hexosaminidase (HEX) A and B in affected brain and liver as compared to controls. Electrophoresis of a liver extract revealed a deficiency of normal HEX A and B in the affected animals. The blocking primary enzyme immunoassay verified the presence of antigenically reactive HEX present in affected cat livers in quantities slightly elevated with respect to the normal HEX concentration in control cats. In leukocytes, obligate heterozygotes had intermediate levels of total HEX activity with a slight increase in the percent activity due to HEX A. Indeed, 4 of 11 phenotypically normal animals in addition to four obligate heterozygotes appear to be carriers using this assay. Affected brain and liver compared with control brain and liver contained a great excess of bound N-acetylneuraminic acid in the Folch upper-phase solids; thin-layer chromatography showed a marked increase in GM2-ganglioside. In summary, we have characterized the pedigree, pathology, and biochemistry of a new feline model of GM2-gangliosidosis which is similar to but different from the only other known feline model.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040927      PMCID: PMC423846          DOI: 10.1172/JCI111997

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

Review 1.  Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease.

Authors:  W G Johnson; R J Desnick; D M Long; H L Sharp; W Krivit; B Brady; R O Brady
Journal:  Birth Defects Orig Artic Ser       Date:  1973-03

2.  Isolation and characterization of glycosphingolipid from animal cells and their membranes.

Authors:  S I Hakomori; B Siddiqui
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

3.  Primary enzyme immunoassay (PEIA): studies of the mutant enzyme in metachromatic leukodystrophy (primary enzyme immunoassay of arylsulfatase-A).

Authors:  E Neuwelt; P F Kohler; J Austin
Journal:  Immunochemistry       Date:  1973-11

4.  Animal models of human ganglioside storage diseases.

Authors:  H J Baker; J A Mole; J R Lindsey; R M Creel
Journal:  Fed Proc       Date:  1976-04

5.  GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency.

Authors:  L C Cork; J F Munnell; M D Lorenz; J V Murphy; H J Baker; M C Rattazzi
Journal:  Science       Date:  1977-05-27       Impact factor: 47.728

6.  Studies on human beta-D-N-acetylhexosaminidases. 3. Biochemical genetics of Tay-Sachs and Sandhoff's diseases.

Authors:  S K Srivastava; E Beutler
Journal:  J Biol Chem       Date:  1974-04-10       Impact factor: 5.157

7.  Tay-Sachs disease heterozygote detection: a quality control study.

Authors:  M M Kaback; L J Shapiro; P Hirsch; C Roy
Journal:  Prog Clin Biol Res       Date:  1977

8.  Enzyme replacement in Tay-Sachs disease.

Authors:  B U von Specht; B Geiger; R Arnon; J Passwell; G Keren; B Goldman; B Padeh
Journal:  Neurology       Date:  1979-06       Impact factor: 9.910

9.  Human beta-glucuronidase deficiency mucopolysaccharidosis: identification of cross-reactive antigen in cultured fibroblasts of deficient patients by enzyme immunoassay.

Authors:  C E Bell; W S Sly; F E Brot
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

10.  Specific binding of 125I-labeled beta-hexosaminidase A to rat brain synaptosomes.

Authors:  J W Kusiak; J H Toney; J M Quirk; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

View more
  12 in total

Review 1.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

2.  Lectin histochemistry of gangliosidosis. I. Neural tissue in four mammalian species.

Authors:  J Alroy; V Goyal; C D Warren
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

3.  Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease.

Authors:  M Cohen-Tannoudji; P Marchand; S Akli; S A Sheardown; J P Puech; C Kress; P Gressens; M C Nassogne; T Beccari; A L Muggleton-Harris
Journal:  Mamm Genome       Date:  1995-12       Impact factor: 2.957

Review 4.  A review of gene therapy in canine and feline models of lysosomal storage disorders.

Authors:  Allison M Bradbury; Brittney L Gurda; Margret L Casal; Katherine P Ponder; Charles H Vite; Mark E Haskins
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-11       Impact factor: 5.032

5.  Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.

Authors:  S Yamanaka; M D Johnson; A Grinberg; H Westphal; J N Crawley; M Taniike; K Suzuki; R L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

Review 6.  Animal models of GM2 gangliosidosis: utility and limitations.

Authors:  Cheryl A Lawson; Douglas R Martin
Journal:  Appl Clin Genet       Date:  2016-07-20

Review 7.  Genetics and Therapies for GM2 Gangliosidosis.

Authors:  Maria Begona Cachon-Gonzalez; Eva Zaccariotto; Timothy Martin Cox
Journal:  Curr Gene Ther       Date:  2018       Impact factor: 4.391

Review 8.  Large animal models of rare genetic disorders: sheep as phenotypically relevant models of human genetic disease.

Authors:  Ashish R Pinnapureddy; Cherie Stayner; John McEwan; Olivia Baddeley; John Forman; Michael R Eccles
Journal:  Orphanet J Rare Dis       Date:  2015-09-02       Impact factor: 4.123

9.  Real-time PCR genotyping assay for GM2 gangliosidosis variant 0 in toy poodles and the mutant allele frequency in Japan.

Authors:  Mohammad Mahbubur Rahman; Akira Yabuki; Moeko Kohyama; Sawane Mitani; Keijiro Mizukami; Mohammad Mejbah Uddin; Hye-Sook Chang; Kazuya Kushida; Miori Kishimoto; Remi Yamabe; Osamu Yamato
Journal:  J Vet Med Sci       Date:  2013-10-25       Impact factor: 1.267

10.  In situ detection of GM1 and GM2 gangliosides using immunohistochemical and immunofluorescent techniques for auxiliary diagnosis of canine and feline gangliosidoses.

Authors:  Moeko Kohyama; Akira Yabuki; Kenji Ochiai; Yuya Nakamoto; Kazuyuki Uchida; Daisuke Hasegawa; Kimimasa Takahashi; Hiroaki Kawaguchi; Masaya Tsuboi; Osamu Yamato
Journal:  BMC Vet Res       Date:  2016-03-31       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.